Synthesis and anticonvulsant activity of 4-(2-(2,6-dimethylphenylamino)-2-oxoethylamino)-N-(substituted)butanamides: A pharmacophoric hybrid approach

Perumal Yogeeswari,* Dharmarajan Sriram, Puppala Sahitya,
Jegadeesan Vaigunda Ragavendran and Velagaleti Ranganadh

Medicinal Chemistry Research Laboratory, Pharmacy Group, Birla Institute of Technology and Science, Pilani 333031, India

Abstract—A series of pharmacophoric hybrids of ameltolide-γ-aminobutyric acid (GABA)-amides was designed, synthesized, and evaluated for their anticonvulsant and neurotoxic properties. Initial anticonvulsant screening was performed using intraperitoneal (ip) maximal electroshock-induced seizure (MES), subcutaneous pentylenetetrazole (scPTZ), and subcutaneous picrotoxin (scPIC)-induced seizure threshold tests. All the compounds had improved lipophilicity and the pharmacological activity profile confirmed their blood–brain barrier penetration. The titled compounds showed promising activity in scPIC screen indicating the involvement of GABA-mediation. Compound 4-(2-(2,6-dimethylaminophenylamino)-2-oxoethylamino)-N-(2,6-dimethylphenyl) butanamide (**7**) emerged as the most potent derivative effective in all the three animal models of seizure with no neurotoxicity at the anticonvulsant dose.
© 2007 Published by Elsevier Ltd.

Epilepsy is a disorder characterized by recurrent seizures of cerebral origin, presenting with episodes of sensory, motor or autonomic phenomenon with or without loss of consciousness. Epilepsy is the second most common chronic neurological condition reported by neurologists.[1] Despite the optimal use of available antiepileptic drugs (AED), many patients with epilepsy fail to experience seizure control and others do so only at the expense of significant toxic side effects.[2] In recent years, the field of antiepileptic drug development is quite dynamic, affording many promising research opportunities. γ-Aminobutyric acid (GABA) is the major inhibitory neurotransmitter in the mammalian brain.[3] It has been well documented that the reduction of GABAergic neuronal activity plays an important role in a number of neurological disorders, including epilepsy.[4,5] The peripheral administration of GABA cannot be usefully performed since this neurotransmitter is able to cross the blood–brain diffusion barrier (BBB) only at extremely

high doses, which produce severe adverse side effects.[6] Hence, over the past few decades, research aimed at achieving successful delivery of GABA into the CNS has resulted in the discovery of various GABA analogs with improved pharmacological activities.[7] We undertook a drug discovery program on designing newer GABA derivatives and recently two series of pharmacophoric hybrids of phthalimide-GABA-anilides/hydrazones were reported as anticonvulsants in which the most active compound was found to be 4-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)-N-(2,6-dimethyl phenyl) butanamide.[8] 4-Amino-N-(2,6-dimethylphenyl)phthalimide was previously designed from the models of ameltolide and thalidomide.[9] In view of the above results, the present work is aimed at combining the pharmacophoric features of ameltolide, a 2,6-dimethylanilide, GABA, and amide as novel class of GABA derivatives.

The synthesis of pharmacophoric hybrids of ameltolide-GABA-amides was accomplished as presented in Scheme 1. The coupling of the 2,6-dimethylphenyl amino group with GABA was achieved via an intermediate acetanilide obtained by chloroacetylation reaction in dichloromethane and the latter was condensed with

**Scheme 1.** Synthetic protocol of the titled compounds.

GABA in ethanol in the presence of triethylamine under microwave[10] for 30 s at 60% intensity to yield 75% of 4-(2-(2,6-dimethylphenylamino)-2-oxoethylamino)butanoic acid (**1**).[14] The 4-(2-(2,6-dimethylaminophenylamino)-2-oxoethylamino)-N-(aryl/alkyl/heteroalkyl) butanamides (**2**–**13**) were obtained by reaction of **1** with respective anilines or alkyl amines or secondary amines at ice cold condition (0–5 °C) in presence of N,N′-dicyclohexyl carbodiimide (DCC) (Table 1). The purity was assessed by TLC; and the assignments of the structures were based on elemental and spectroscopic methods of analysis. The IR spectral data of the synthesized compounds (**1**–**13**) were identical in the following aspects, 3200–3100, 3030, 1640, 1400, 780 cm^{-1}. In the ^{1}H NMR spectra the signals of the respective protons of the prepared butanamides were verified on the basis of their chemical shifts, multiplicities, and coupling constants. The spectra showed a signal at $\delta \sim 2.0$ ppm correlated to be the amino group at γ carbon of GABA; NH proton attached to aromatic nucleus appeared at $\delta \sim 10.02$ ppm in addition to a singlet signal at $\delta \sim 3.49$ ppm corresponding to the methylene proton of COCH$_2$N group. Elemental analysis results were within ±0.4% of the theoretical values. log P for all the synthesized compounds were calculated using chemdraw ultra 9.0 (Cambridge software).

The anticonvulsant activity of the synthesized compounds (**1**–**13**) was determined using three animal models of seizure which included maximal electroshock seizure[11] (MES), subcutaneous pentylenetetrazole[12] (scPTZ), and intraperitoneal picrotoxin[13] (ipPIC)-induced seizure threshold tests. The acute neurological toxicity was determined in the rotorod test. The results are summarized along with the data for standard drugs in Table 2. All of the compounds except **4**, **8**, **12**, and **13** showed activity in the MES screen at 100 mg/kg except **10** at 300 mg/kg after 0.5 h of drug administration indicative of their ability to prevent seizure spread. In the subcutaneous pentylenetetrazole (scPTZ) screen, a test used to identify compounds that elevate seizure threshold, only two compounds with dimethyl phenyl group (**6** and **7**) showed protection at 300 and 30 mg/kg, respectively. In the scPIC-induced seizure threshold test, all of the compounds exhibited activity indicative of the possible involvement of GABA-mediation in the anticonvulsant action. The compound 2,6-dimethylanilide (**7**) showed pronounced activity at 10 mg/kg and compounds that showed protection at 30 mg/kg include **1**, **3**, **4**, **9**, and **13**. All other compounds showed activity at 100 mg/kg. In general, it appears that except compounds **4**, **8**, **12**, and **13**, all other compounds were found to be effective in at least two models of seizure with compounds **6** and **7** effective in three animal models of seizures. In the acute neurological toxicity screen, the compounds **1**–**5**, **7**–**9**, and **13** emerged as promising anticonvulsants with less or no neurotoxicity. There was no separation between the anticonvulsant dose and the neurotoxic dose (300 mg/kg) for compounds **6**, and **10**–**12**. Compound 4-(2-(2,6-dimethylaminophenylamino)-2-oxoethylamino)-N-(2,6-dimethylphenyl) butanamide (**7**)[15] emerged as the most potent derivative effective in all the three animal models of seizure with no neurotoxicity at the anticonvulsant dose when compared to the standard drugs.

In the present study, we have demonstrated that combination of ameltolide-GABA-amide pharmacophores

Table 1. Physical constants of the titled compounds

Compound	NRR[1]	Yield (%)	Mp (°C)	Molecular formula[a]	Molecular weight	log P[b]
1	—	60	133	$C_{14}H_{20}N_2O_3$	264	0.54
2	–NHPh	60	92	$C_{20}H_{25}N_3O_2$	339	2.44
3	–NH(2-BrPh)	59	123	$C_{20}H_{24}N_3O_2Br$	418	3.27
4	–NH(3-CH$_3$Ph)	81	131	$C_{21}H_{27}N_3O_2$	353	2.93
5	–NH(3-Cl-2-CH$_3$Ph)	84	128	$C_{21}H_{26}N_3O_2Cl$	388	3.49
6	–NH(2,4-dimethylPh)	63	74	$C_{22}H_{29}N_3O_2$	367	3.42
7	–NH(2,6-dimethylPh)	62	113	$C_{22}H_{29}N_3O_2$	367	3.42
8	–N(CH$_3$)$_2$	83	121	$C_{16}H_{25}N_3O_2$	291	1.01
9	–N(n-Bu)$_2$	92	112	$C_{22}H_{37}N_3O_2$	375	3.50
10	–N(Ph)$_2$	63	93	$C_{26}H_{29}N_3O_2$	476	4.34
11	(piperidinyl)	73	98	$C_{19}H_{29}N_3O_2$	331	1.75
12	(4-methylpiperidinyl)	75	104	$C_{20}H_{21}N_3O_2$	345	2.08
13	(4-(3-trifluoromethylphenyl)piperazinyl)	68	223	$C_{25}H_{31}N_3O_2F_3$	490	3.77

[a] Elemental analyses for C, H, N were within ±0.4% of the theoretical values.
[b] Calculated using chemdraw ultra 9.0 program (Cambridge software).

Table 2. Anticonvulsant activity and minimal motor impairment of the titled compounds

Compound	Intraperitoneal injection in mice[a]					
	MES screen	scPTZ screen	scPIC screen		Neurotoxicity	
	0.5 h	0.5 h	0.5 h	4 h	0.5 h	4 h
1	100	—	30	100	300	—
2	100	—	100	—	300	300
3	100	—	30	30	300	300
4	—	—	30	100	300	—
5	100	—	100	100	300	—
6	100	300	100	100	300	300
7	100	30	10	30	300	—
8	—	—	100	100	—	300
9	100	—	30	100	300	—
10	300	—	100	300	300	—
11	100	—	100	—	100	—
12	—	—	100	100	100	100
13	—	—	30	100	—	—
Phenytoin	30	—	—	—	100	100
Ethosuximide	—	100	—	—	—	—
Phenobarbital	100	30	30	100	100	300

[a] Doses of 30, 100, and 300 mg/kg were administered. Control study with vehicle treatment produced no anticonvulsant activity. The figures in the table indicate the minimum dose whereby bioactivity was demonstrated in half or more of the mice. The dash (—) indicates an absence of activity at the maximum dose administered (300 mg/kg).

yielded newer prototypic GABA derivatives with potential activity in the preliminary testing. The pharmacological activity profile confirmed their blood–brain barrier penetration. Thus, these newer derivatives would be beneficial for a wide range of seizures and furthermore this logical thinking can be extended in combining other anticonvulsant pharmacophores in the future.

Acknowledgment

References and notes

1. Gasior, M.; Carter, R. B.; Goldberg, S. R.; Witkin, J. M. *J. Pharmacol. Exp. Ther.* **1997**, *282*, 543.
2. Coatsworth, J. J. NINDS monograph No. 12, 73-15, HEW publication U.S. Government Printing Office, 1971.
3. Sivilotti, L.; Nistri, A. *Prog. Neurobiol.* **1991**, *36*, 35.
4. Meldrum, B. S. *Int. Rev. Neurobiol.* **1975**, *17*, 1.
5. Loscher, W. In *Epilepsy and GABA Receptor Agonists: Basic and Therapeutic Research (L.E.R.S. Monograph Series)*; Bartholini, G., Bossi, L., Lloyd, K. G., Morselli, P. L., Eds.; Raven Press: New York, 1985; pp 109–119.
6. Toth, E.; Lajhta, A.; Sarhan, S.; Seiler, N. *Neurochem. Res.* **1983**, *8*, 291.
7. Yogeeswari, P.; Ragavendran, J. V.; Sriram, D. *Recent Patents on CNS Drug Discov.* **2006**, *1*, 113.
8. Ragavendran, J. V.; Sriram, D.; Patel, S. K.; Reddy, I. V.; Bharathwajan, N.; Stables, J.; Yogeeswari, P. *Eur. J. Med. Chem.* **2006**, *42*, 146.
9. Vamecq, J.; Bac, P.; Herrenknecht, C.; Maurois, P.; Delcourt, P.; Stables, J. P. *J. Med. Chem.* **2000**, *43*, 1311.
10. A domestic microwave oven with the following specifications had been used: Make LG; single irradiation type Input 220 V–50 Hz, 980 W, 4.7 A; Frequency 2450 MHz.
11. Porter, R. J.; Cereghino, J. J.; Gladding, G. D.; Hessie, B. J.; Kupferberg, H. J.; Scoville, B.; White, B. *Cleveland Clin. Quart.* **1984**, *51*, 293.
12. Krall, R. L.; Penry, J. K.; White, B. G.; Kupferbeng, H. J.; Swinyard, E. A. *Epilepsia* **1978**, *19*, 409.
13. Belelli, D.; Bolger, M. B.; Gee, K. W. *Eur. J. Pharmacol.* **1989**, *166*, 325.
14. Characterization data for 4-(2-(2,6-dimethylphenylamino)-2-oxoethylamino) butanoic acid (**1**): ^{1}H NMR, δ (ppm): 1.70 (m, 2H, CH_2 β to COOH), 2.0 (s, 1H, $NHCH_2$, D_2O exchangeable), 2.10 (s, 6H, Ar-CH_3), 2.23 (t, 2H, CH_2 α to COOH), 2.59 (t, 2H, CH_2 γ to COOH), 3.55 (s, 2H, CH_2NH), 7.1–7.34 (m, 3H, Ar-H), 9.98 (s, 1H, Ar-NH, D_2O exchangeable), 12.20 (s, 1H, OH of COOH, D_2O exchangeable). Calcd for $C_{14}H_{20}N_2O_3$: C, 63.62; H, 7.63; N, 10.60. Found: C, 63.66; H, 7.69, N, 10.62.
15. Characterization data for 4-(2-(2,6-dimethylaminophenylamino)-2-oxoethylamino)-*N*-(2,6-dimethylphenyl) butanamide (**7**): ^{1}H NMR, δ (ppm): 1.78 (m, 2H, CH_2 β to COOH), 2.0 (s, 1H, $NHCH_2$, D_2O exchangeable), 2.12 (s, 12H, Ar-CH_3), 2.22 (t, 2H, CH_2 α to COOH), 2.55 (t, 2H, CH_2 γ to COOH), 3.49 (s, 2H, CH_2NH), 7.1–7.4 (m, 6H, Ar-H), 10.03 (s, 2H, Ar-NH, D_2O exchangeable). Calcd for $C_{22}H_{29}N_3O_2$: C, 71.90; H, 7.95; N, 11.43. Found: C, 71.86; H, 7.91; N, 11.54.